| ONCOTELIC |
ONCOTELIC |
92%
|
On July 1, 2024, we entered into a Master Services Agreement with Oncotelic whereby we perform advisory and related services in connection with studies and projects. During the years ended December 3… |
| AZN |
AstraZeneca PLC |
72%
|
Reciprocal relationship from AZN graph: Reciprocal relationship from CPMV graph: Reciprocal relationship from AZN graph: Reciprocal relationship from CPMV graph: ate our business without infringing o… |
| AZN |
AstraZeneca PLC |
72%
|
ate our business without infringing on third-party patent rights. We may be required to obtain licenses to patents or other proprietary rights from third parties to develop, manufacture and commercia… |
| BMY |
Bristol-Myers Squibb Company |
72%
|
ate our business without infringing on third-party patent rights. We may be required to obtain licenses to patents or other proprietary rights from third parties to develop, manufacture and commercia… |
| BMY |
Bristol-Myers Squibb Company |
72%
|
Reciprocal relationship from BMY graph: Reciprocal relationship from CPMV graph: ate our business without infringing on third-party patent rights. We may be required to obtain licenses to patents or … |
| BMYMP |
Bristol-Myers Squibb Co |
72%
|
ate our business without infringing on third-party patent rights. We may be required to obtain licenses to patents or other proprietary rights from third parties to develop, manufacture and commercia… |
| BMYMP |
Bristol-Myers Squibb Co |
72%
|
Reciprocal relationship from BMYMP graph: Reciprocal relationship from CPMV graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from CPMV graph: ate our business without infringi… |
| MRK |
Merck & Co., Inc. |
72%
|
ate our business without infringing on third-party patent rights. We may be required to obtain licenses to patents or other proprietary rights from third parties to develop, manufacture and commercia… |
| MRK |
Merck & Co., Inc. |
72%
|
Reciprocal relationship from MRK graph: Reciprocal relationship from CPMV graph: Reciprocal relationship from MRK graph: Reciprocal relationship from CPMV graph: Reciprocal relationship from MRK grap… |
| NVSEF |
Novartis AG |
72%
|
Reciprocal relationship from NVSEF graph: Reciprocal relationship from CPMV graph: ate our business without infringing on third-party patent rights. We may be required to obtain licenses to patents o… |
| NVSEF |
Novartis AG |
72%
|
ate our business without infringing on third-party patent rights. We may be required to obtain licenses to patents or other proprietary rights from third parties to develop, manufacture and commercia… |
| OTLC |
Oncotelic Therapeutics, Inc. |
72%
|
ate our business without infringing on third-party patent rights. We may be required to obtain licenses to patents or other proprietary rights from third parties to develop, manufacture and commercia… |
| OTLC |
Oncotelic Therapeutics, Inc. |
72%
|
Reciprocal relationship from OTLC graph: Reciprocal relationship from CPMV graph: Reciprocal relationship from OTLC graph: Reciprocal relationship from CPMV graph: Reciprocal relationship from OTLC g… |
| ISSUER-DIRECT-CORPORATION |
ISSUER-DIRECT-CORPORATION |
62%
|
ovision of our amended and restated certificate of incorporation or amended and restated bylaws or Delaware law that has the effect of delaying or deterring a change in control could limit the opport… |
| SECURITIES-INVESTOR-PROTECTION-CORPORATION |
SECURITIES-INVESTOR-PROTECTION-CORPORATION |
62%
|
ts have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) and include the accounts of Mosaic ImmunoEngineering, Inc. and our subsidiaries. All inte… |
